To date, five inhibitors of the PD-1/PD-L1 axis have been approved for advanced NSCLC: of these, pembrolizumab, nivolumab, and cemiplimab target PD-1, whilst durvalumab and atezolizumab target its ligand PD-L1. The gene discussed is CD274; the disease is non-small cell lung carcinoma.